Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. Read more about Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.
Breast density influences tumor subtypes and tumor aggressiveness. Read more about Breast density influences tumor subtypes and tumor aggressiveness.
Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study. Read more about Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study.
Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. Read more about Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement.
Independent prognostic value of screen detection in invasive breast cancer. Read more about Independent prognostic value of screen detection in invasive breast cancer.
Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. Read more about Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers.
Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. Read more about Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study.
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. Read more about Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies.
DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. Read more about DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. Read more about Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.
